+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Comments

Loading...

Axsome Therapeutics

AXSMNASDAQ

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$86.05

1.21.41%

At Close: -

$86.88

0.830.96%

After Hours: 5:44 PM EDT

15 minutes delayed

Q2 2024 Earnings in 14 days from now on Mon Aug 5th, before the market open

Axsome Therapeutics (AXSM) Forecast

News

Earnings Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Latest news for Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics Stock (NASDAQ: AXSM)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Monday, July 22, 2024

Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future
Vandana Singh
RBC Capital Reiterates Outperform on Axsome T...
Benzinga Newsdesk
Needham Initiates Coverage On Axsome Therapeu...
Benzinga Newsdesk

Thursday, July 18, 2024

Wall Street Analysts Predict a 49.36% Upside in Axsome: Here's What You Should Know
Zacks
Decoding 9 Analyst Evaluations For Axsome Therapeutics
Benzinga Insights
B of A Securities Maintains Neutral on Axsome...
Benzinga Newsdesk

Wednesday, June 12, 2024

Mizuho Reiterates Buy on Axsome Therapeutics,...
Benzinga Newsdesk

Tuesday, June 11, 2024

Unpacking the Latest Options Trading Trends in Axsome Therapeutics
Benzinga Insights
Axsome Therapeutics shares are trading lower ...
Benzinga Newsdesk
Watching Axsome Therapeutics Shares, Culper R...
Benzinga Newsdesk

Thursday, June 06, 2024

HC Wainwright & Co. Reiterates Buy on Axsome ...
Benzinga Newsdesk

Wednesday, June 05, 2024

15 Analysts Assess Axsome Therapeutics: What You Need To Know
Benzinga Insights
RBC Capital Maintains Outperform on Axsome Th...
Benzinga Newsdesk
Axsome Therapeutics Announced That It Has Ent...
Benzinga Newsdesk

Wednesday, May 29, 2024

Axsome Therapeutics To Highlight Solriamfetol...
Benzinga Newsdesk

Tuesday, May 28, 2024

Axsome Unveils New Findings on Auvelity and A...
Benzinga Newsdesk
Hello Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Avi Kapoor

Wednesday, May 08, 2024

Mizuho Maintains Buy on Axsome Therapeutics, ...
Benzinga Newsdesk

Tuesday, May 07, 2024

Citigroup Maintains Buy on Axsome Therapeutic...
Benzinga Newsdesk
Baird Maintains Outperform on Axsome Therapeu...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Axsome ...
Benzinga Newsdesk

Monday, May 06, 2024

Axsome Therapeutics Q1 2024 GAAP EPS $(1.44) ...
Benzinga Newsdesk

Monday, April 29, 2024

Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights
Benzinga Insights
Morgan Stanley Upgrades Axsome Therapeutics t...
Benzinga Newsdesk

Wednesday, April 10, 2024

Analyst Ratings For Axsome Therapeutics
Benzinga Insights
Cantor Fitzgerald Reiterates Overweight on Ax...
Benzinga Newsdesk

Tuesday, April 02, 2024

HC Wainwright & Co. Maintains Buy on Axsome T...
Benzinga Newsdesk

Monday, April 01, 2024

Axsome Therapeutics Has Initiated ENGAGE Phas...
Benzinga Newsdesk

Thursday, March 28, 2024

Mizuho Maintains Buy on Axsome Therapeutics, ...
Benzinga Newsdesk

Tuesday, March 26, 2024

Truist Securities Maintains Buy on Axsome The...
Benzinga Newsdesk
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
Avi Kapoor
RBC Capital Maintains Outperform on Axsome Th...
Benzinga Newsdesk
Citigroup Maintains Buy on Axsome Therapeutic...
Benzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Axsome T...
Benzinga Newsdesk

Monday, March 25, 2024

What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?
Vandana Singh
Axsome Therapeutics shares are trading higher...
Benzinga Newsdesk
Axsome Therapeutics' AXS-12 (Reboxetine) Achi...
Benzinga Newsdesk

Wednesday, March 20, 2024

HC Wainwright & Co. Reiterates Buy on Axsome ...
Benzinga Newsdesk

Tuesday, March 19, 2024

What Analysts Are Saying About Axsome Therapeutics Stock
Benzinga Insights
Axsome Therapeutics Announced The First Patie...
Benzinga Newsdesk
Baird Initiates Coverage On Axsome Therapeuti...
Benzinga Newsdesk

Monday, March 04, 2024

HC Wainwright & Co. Reiterates Buy on Axsome ...
Benzinga Newsdesk

Tuesday, February 27, 2024

What Analysts Are Saying About Axsome Therapeutics Stock
Benzinga Insights
Mizuho Maintains Buy on Axsome Therapeutics, ...
Benzinga Newsdesk

Wednesday, February 21, 2024

Guggenheim Maintains Buy on Axsome Therapeuti...
Benzinga Newsdesk
RBC Capital Maintains Outperform on Axsome Th...
Benzinga Newsdesk
Cantor Fitzgerald Maintains Overweight on Axs...
Benzinga Newsdesk
CORRECTION: Axsome Therapeutics Q4 Adjusted E...
Benzinga Newsdesk

Tuesday, February 20, 2024

Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones
Vandana Singh
Cantor Fitzgerald Reiterates Overweight on Ax...
Benzinga Newsdesk

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved